Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: Effects on autonomic modulation of the cardiovascular system

Hypertension Research

Volumn 31, Issue 3, 2008, Pages 443-453

  Guzik, Przemyslaw ^a   Wykretowicz, Andrzej ^a   Krauze, Tomasz ^a   Piskorski, Jaroslaw ^b   Adamska, Karolina ^a   Milewska, Agata ^a   Wesseling, Karel H ^c   Wysocki, Henryk ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF ZIELONA GÓRA   (Poland)

^c BMEYE BV   (Netherlands)

Author keywords

Baroreflex sensitivity; Doxazosin; Heart rate variability; Phase rectified signal averaging; Poincar plots of RR intervals

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG FORMULATION; ELECTROCARDIOGRAPHY; FEMALE; GENDER; HEART CYCLE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HYPERTENSION; MALE; MORNING DOSAGE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INVASIVE MEASUREMENT; PRESSORECEPTOR REFLEX; PULSE PRESSURE; SINGLE DRUG DOSE; SPECTROSCOPY; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM; BAROREFLEX; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CIRCADIAN RHYTHM; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 42649107776     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.443     Document Type: Article

References (31)

1. Ajiki K, Murakawa Y, Yanagisawa-Miwa A, et al: Autonomic nervous system activity in idiopathic dilated cardiomyopathy and in hypertrophic cardiomyopathy. Am J Cardiol 1993; 71: 1316-1320.
2. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-484.
3. Kleiger RE, Stein PK, Bigger JT Jr: Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005; 10: 88-101.
4. Guzik P, Piskorski J, Krauze T, et al: Correlations between Poincaré plot and conventional heart rate variability parameters assessed during paced breathing. J Physiol Sci 2007; 57: 63-71.
5. Westerhof BE, Gisolf J, Stok WJ, Wesseling KH, Karemaker JM: Time-domain cross-correlation baroreflex sensitivity: performance on the EUROBAVAR data set. J Hypertens 2004; 22: 1371-1380.
6. Sega R, Corrao G, Bombelli M, et al: Blood pressure variability and organ damage in a general population: results from the PAMELA study. Hypertension 2002; 39: 710-714.
7. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD: Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-565.
8. Ylitato A, Airaksinen KE, Sellin L, Huikuri HV: Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension. Am J Cardiol 1999; 83: 885-889.
9. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29: S1-S105.
10. Ebata H, Hojo Y, Ikeda U, Ishida H, Natsume T, Shimada K: Differential effects of an alpha 1-blocker (doxazosin) on diurnal blood pressure variation in dipper and non-dipper type hypertension. Hypertens Res 1995; 18: 125-130.
11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
12. Furberg CD: Doxazosin, an inferior antihypertensive agent? J Hum Hypertens 2002; 16: 375-377.
13. Stoschitzky K, Donnerer J, Klein W, et al: Different effects of propranolol, bisoprolol, carvedilol and doxazosin on heart rate, blood pressure, and plasma concentrations of epinephrine and norepinephrine. J Clin Basic Cardiol 2003; 6: 69-72.
14. Os I, Stokke HP, Doxazosin Investigators' Study Group: Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1999; 33: 791-797.
15. de Alvaro F, Hernandez-Presa MA, ASOCIA Study: Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study. J Cardiovasc Pharmacol 2006; 47: 271-276.
16. Brennan M, Palaniswami M, Kameni P: Do existing measures of Poincaré plot geometry reflect nonlinear features of heart rate variability? IEEE Trans Biomed Eng 2001; 48:1342-1347.
17. Piskorski J, Guzik P: Geometry of the Poincare plot of RR intervals and its asymmetry in healthy adults. Physiol Meas 2007; 28: 287-300.
18. Bauer A, Kantelhardt JW, Barthel P, et al: Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 2006; 367: 1674-1681.
19. Imholz BP, Settels JJ, van der Meitacker A-H, Wesseling KH, Wieling W: Non-invasive continuous finger blood pressure measurement during orthostatic stress compared to intra-arterial pressure. Cardiovasc Res 1990; 24: 214-221.
20. Campo C, Segura J, Roldan C, Alcazar JM, Rodicio JL, Ruilope LM: Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. Blood Press Suppl 2003; 2: 16-21.
21. Pessina AC, Ciccariello L, Perrone F, et al: Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 2006; 16: 137-147.
22. Joles JA, Koomans HA: Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706.
23. Ichikawa M, Suzuki H, Kumagai K, et al: Differential modulation of baroreceptor sensitivity by long-term antihypertensive treatment. Hypertension 1995; 26: 425-431.
24. Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M: Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension. Angiology 1995; 46: 11-18.
25. Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M: Doxazosin withdrawal and ambulatory blood pressure monitoring in normotensive subjects. Angiology 1994; 45: 17-23.
26. Ueshiba H, Miyachi Y: Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003; 35: 532-536.
27. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalitie" the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
28. Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM: Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994; 309: 226-230.
29. Benetos A, Safar M, Rudnichi A, et al: Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410-1415.
30. Komai N, Ohishi M, Moriguchi A, et al: Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res 2002; 25: 5-10.
31. Wykretowiez A, Guzik P, Krauze T, Adamska K, Milewska A, Wysocki H: Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol- mediated arterial vasodilation. Br J Clin Pharmacol 2007; 64: 792-795.